Cinclus Pharma Holding

Linaprazan Glurate Will Revolutionize Global Gastrointestinal Care

AnalystHighTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

24 Aug 25

Updated

24 Aug 25

AnalystHighTarget's Fair Value

SEK 75.00

79.2% undervalued

24 Aug

SEK 15.58

-49.0%

0.5%

-49.0%

0.5%

Author's Valuation

SEK 75.0

79.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

SEK 75.0

79.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

40.90%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.92%

Calculation

SEK 72.10m

Earnings '28

55.26x

PE Ratio '28

SEK 3.98b

Market Cap '28

SEK 3.98b

Market Cap '28

46.54m

No. shares '28

SEK 85.62

Share Price '28

SEK 85.62 Share Price '28

Discounted to 2025 @ 4.92% p.a.

SEK 74.13

Fair Value '25